Omnicell

Omnicell

About Omnicell

Simplify's Rating
Why Omnicell is rated
B+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated C on Rating Differentiation

Industries

Robotics & Automation

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1992

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Omnicell's focus on data analytics optimizes specialty pharmacy operations.
  • OmniSphere aligns with the growing demand for cloud-based healthcare solutions.
  • Telepharmacy services expand Omnicell's reach in rural and underserved areas.

What critics are saying

  • Increased competition from major players in the specialty pharmacy market.
  • Challenges in achieving seamless data exchange and interoperability.
  • Potential financial risk from $172.5 million convertible senior notes issuance.

What makes Omnicell unique

  • Omnicell leverages AI and machine learning for enhanced medication management.
  • Omnicell's OmniSphere offers scalable, cloud-based solutions for medication management.
  • Collaboration with LSPedia enhances supply chain compliance and traceability.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$170M

Above

Industry Average

Funded Over

2 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Street Insider
Mar 24th, 2025
Omnicell (OMCL) appoints Perry Genova as CTO

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.

MarketScreener
Mar 12th, 2025
Omnicell, Inc. Announces Step Down of Nchacha Etta as Executive Vice President Effective September 15, 2025

Omnicell, Inc. announced that Nchacha Etta will be stepping down from his role as Executive Vice President effective September 15, 2025 or until a successor is named.

Hit Consultant
Mar 4th, 2025
Data Is The Cure: Why Specialty Pharmacies Need Analytics To Thrive In 2024

Matt Manning, Sr. Director of Operations for Health Systems at OmnicellTo meet the rising demand for drugs to treat rare and chronic conditions, the industry’s largest players (e.g., CVS Health, Cigna, and UnitedHealth Group) have moved quickly to derive two-thirds of their prescription revenues from specialty dispensing. Health systems are following suit, rapidly launching entity-owned specialty pharmacies that enable these providers to strengthen the continuity of care they deliver to patients. As providers stake out claim in the competitive $68.3 billion specialty drug market, strategic application of data analytics to provide key fulfillment insights could be the differentiator that ensures success.Challenges Associated with Entity-Owned Specialty PharmaciesA fully optimized, entity-owned specialty pharmacy is a key way for health systems to improve patient care by increasing access to specialty medications and reducing the turnaround time for prescription fulfillment while at the same time generating revenue via increased script capture. However, challenges in key operational areas prevent health systems from realizing these benefits, including:Interoperability: As seamless data exchange remains the modern healthcare standard. Pharmacies with connectivity gaps suffer hits to patient experience and care coordination due to not having the most up-to-date information to influence patient onboarding, prescribing decisions, and patient communications.As seamless data exchange remains the modern healthcare standard

HR Tech Wire
Jan 14th, 2025
Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025

Keles Care
Jan 10th, 2025
David Buller - KELES Managing Partner

After scaling the company to 50 staff and annual revenues exceeding $10 million, Avantec was acquired by Omnicell (NASDAQ: OMCL) in 2015.

Recently Posted Jobs

Sign up to get curated job recommendations

Omnicell is Hiring for 118 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Omnicell's jobs every few hours, so check again soon! Browse all jobs →